{"id":"1wipv-2sipv","safety":{"commonSideEffects":[{"rate":null,"effect":"Local injection site reactions (pain, redness, swelling)"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Irritability"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine works by introducing inactivated poliovirus antigens to stimulate humoral and cellular immune responses without causing disease. The combination of whole-virus and split-virus formulations is designed to optimize immunogenicity and safety profile. This heterologous prime-boost approach aims to enhance protective antibody responses against all three poliovirus serotypes.","oneSentence":"This is an inactivated polio vaccine combining one dose of whole-virus IPV with two doses of split-virus IPV to provide immunization against poliovirus types 1, 2, and 3.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:25:03.153Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Poliomyelitis prevention in infants and children"}]},"trialDetails":[{"nctId":"NCT07457060","phase":"PHASE4","title":"Phase IV Clinical Study of Sequential Vaccination of Sabin Strain and Wild Strain Inactivated Poliovirus Vaccine","status":"RECRUITING","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2025-11-27","conditions":"Poliomyelitis","enrollment":480}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"1wIPV+2sIPV","genericName":"1wIPV+2sIPV","companyName":"Sinovac Biotech Co., Ltd","companyId":"sinovac-biotech-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"Researchers conducted a Phase IV clinical study (NCT07457060) to evaluate the immunogenicity and safety of a sequential vaccination of Sabin strain and wild strain inactivated poliovirus vaccine, specifically comparing the 1wIPV+2sIPV regimen. This study was conducted by Sinovac Biotech Co., Ltd. to assess the vaccine's effectiveness against poliomyelitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}